Avadel Pharmaceuticals PLC. (AVDL) Receives Daily News Impact Score of 0.20
Media headlines about Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Avadel Pharmaceuticals PLC. earned a news impact score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.7911073280585 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Featured Company News – Alkermes Presents Positive Pre-Clinical Data On Immuno-Oncology Drug Candidate ALKS 4230 (finance.yahoo.com)
- Avadel Pharmaceuticals’ (AVDL) CEO Michael Anderson on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Avadel Pharmaceuticals Reports Third Quarter 2017 Results (finance.yahoo.com)
- Avadel posts 3Q profit (finance.yahoo.com)
- Avadel Pharmaceuticals PLC. (AVDL) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS (americanbankingnews.com)
Avadel Pharmaceuticals PLC. (AVDL) traded up $0.18 during trading on Friday, reaching $9.19. The company’s stock had a trading volume of 331,900 shares, compared to its average volume of 210,580. The company has a current ratio of 2.30, a quick ratio of 2.24 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $368.37, a price-to-earnings ratio of 17.02 and a beta of 1.41. Avadel Pharmaceuticals PLC. has a one year low of $8.14 and a one year high of $12.30.
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.13. The company had revenue of $39.68 million for the quarter, compared to analyst estimates of $38.22 million. Avadel Pharmaceuticals PLC. had a return on equity of 39.24% and a net margin of 44.47%. The business’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.08) earnings per share. equities analysts forecast that Avadel Pharmaceuticals PLC. will post 0.3 EPS for the current year.
AVDL has been the topic of several recent analyst reports. Zacks Investment Research raised Avadel Pharmaceuticals PLC. from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Monday, July 17th. Roth Capital set a $15.00 price target on Avadel Pharmaceuticals PLC. and gave the company a “buy” rating in a research note on Wednesday, August 9th. Ladenburg Thalmann Financial Services boosted their price target on Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a research note on Thursday, September 7th. Finally, Langenberg & Company reaffirmed a “buy” rating and issued a $30.00 price target (up previously from $27.00) on shares of Avadel Pharmaceuticals PLC. in a research note on Thursday, September 7th.
In other Avadel Pharmaceuticals PLC. news, CEO Michael S. Anderson acquired 4,000 shares of Avadel Pharmaceuticals PLC. stock in a transaction on Tuesday, September 12th. The shares were bought at an average price of $9.80 per share, with a total value of $39,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Greg J. Divis acquired 10,600 shares of Avadel Pharmaceuticals PLC. stock in a transaction on Tuesday, September 12th. The stock was acquired at an average cost of $9.32 per share, for a total transaction of $98,792.00. Following the purchase, the insider now owns 10,600 shares of the company’s stock, valued at approximately $98,792. The disclosure for this purchase can be found here. In the last three months, insiders acquired 46,855 shares of company stock worth $445,058. Insiders own 5.07% of the company’s stock.
Avadel Pharmaceuticals PLC. Company Profile
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.
Receive News & Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related companies with MarketBeat.com's FREE daily email newsletter.